BioNTech SE (BNTX) has released an update.
BioNTech SE has announced that the FDA has implemented a partial clinical hold on a Phase 1 trial for a BioNTech-partnered cancer drug, citing potential risks at higher doses. The trial, aimed at treating advanced cancer patients with a new antibody-drug conjugate, has paused new patient enrollment in the U.S. as the company works to address the FDA’s safety concerns.
For further insights into BNTX stock, check out TipRanks’ Stock Analysis page.
